Sorafenib Reduced Significantly Heptopulmonary Shunt in a Large Hepatocelullar Carcinoma.
Aged, 80 and over
Antineoplastic Agents
/ therapeutic use
Carcinoma, Hepatocellular
/ diagnostic imaging
Chemoradiotherapy
Humans
Liver Neoplasms
/ diagnostic imaging
Male
Radiopharmaceuticals
/ therapeutic use
Sorafenib
/ therapeutic use
Technetium Tc 99m Aggregated Albumin
Yttrium Radioisotopes
/ therapeutic use
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
pubmed:
6
11
2018
medline:
15
1
2019
entrez:
6
11
2018
Statut:
ppublish
Résumé
An 81-year-old man with a large hepatocellular carcinoma was referred in our institution for Y radioembolization (RE). The preliminary arteriography using Tc-macroaggregate albumin demonstrated an important hepatopulmonary shunt. It was an exclusion criterion for RE due to high risks of lung radiations. Then, the patient was treated with sorafenib during 4 months, stopped because of grade 3 toxicity. A second liver arteriography was performed, and Tc-macroaggregate albumin imaging showed an important reduction of the lung shunt. Transient therapy with sorafenib permitted to close the lung shunt and was a bridge for RE.
Identifiants
pubmed: 30394928
doi: 10.1097/RLU.0000000000002369
doi:
Substances chimiques
Antineoplastic Agents
0
Radiopharmaceuticals
0
Technetium Tc 99m Aggregated Albumin
0
Yttrium Radioisotopes
0
Sorafenib
9ZOQ3TZI87
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM